ATE428432T1 - Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung - Google Patents

Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung

Info

Publication number
ATE428432T1
ATE428432T1 AT02754173T AT02754173T ATE428432T1 AT E428432 T1 ATE428432 T1 AT E428432T1 AT 02754173 T AT02754173 T AT 02754173T AT 02754173 T AT02754173 T AT 02754173T AT E428432 T1 ATE428432 T1 AT E428432T1
Authority
AT
Austria
Prior art keywords
active carbon
oral pharmaceutical
pharmaceutical formulation
activated charcoal
starch
Prior art date
Application number
AT02754173T
Other languages
English (en)
Inventor
Decai Chen
Original Assignee
Decai Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decai Chen filed Critical Decai Chen
Application granted granted Critical
Publication of ATE428432T1 publication Critical patent/ATE428432T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02754173T 2001-09-13 2002-09-09 Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung ATE428432T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB01128840XA CN1281217C (zh) 2001-09-13 2001-09-13 活性碳在制备治疗甲亢症的口服药物制剂中的应用
PCT/CN2002/000630 WO2003022292A1 (fr) 2001-09-13 2002-09-09 Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation

Publications (1)

Publication Number Publication Date
ATE428432T1 true ATE428432T1 (de) 2009-05-15

Family

ID=4668655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754173T ATE428432T1 (de) 2001-09-13 2002-09-09 Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung

Country Status (8)

Country Link
US (1) US20040265299A1 (de)
EP (1) EP1437140B1 (de)
JP (1) JP2005524604A (de)
CN (1) CN1281217C (de)
AT (1) ATE428432T1 (de)
DE (1) DE60231997D1 (de)
ES (1) ES2322041T3 (de)
WO (1) WO2003022292A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497351T1 (de) * 2003-06-20 2011-02-15 Hills Pet Nutrition Inc Verfahren für die schilddrüsenüberfunktion bei der katze sowie zusammensetzungen mit eingeschränktem jodgehalt
US8501223B2 (en) 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism
PL2222314T3 (pl) * 2007-11-23 2013-07-31 Pharmalundensis Ab Zastosowanie i sposoby uzyskania rozluźnienia oskrzeli
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
CN110151792A (zh) * 2019-06-06 2019-08-23 合肥元佑健康管理有限公司 一种治疗甲亢的中药方及其制备方法
WO2021134482A1 (en) * 2019-12-31 2021-07-08 Fresenius Medical Care Deutschland Gmbh Direct compressed activated carbon tablet formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642986A (en) * 1970-04-01 1972-02-15 William Arthur Welch Aspirin-charcoal compositions
US5554370A (en) * 1994-05-27 1996-09-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for the treatment of inflammatory bowel diseases

Also Published As

Publication number Publication date
CN1406587A (zh) 2003-04-02
ES2322041T3 (es) 2009-06-16
WO2003022292A1 (fr) 2003-03-20
EP1437140A1 (de) 2004-07-14
EP1437140A4 (de) 2005-06-22
CN1281217C (zh) 2006-10-25
JP2005524604A (ja) 2005-08-18
EP1437140B1 (de) 2009-04-15
DE60231997D1 (de) 2009-05-28
US20040265299A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
JP2003520232A5 (de)
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
JP2004532810A5 (de)
NO304638B1 (no) Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander
ES2111168T3 (es) Comprimidos de liberacion sostenida que contienen bupropion.
DE59209706D1 (de) S(+)-Ibuprofen enthaltende Arzneimittel
AU2916792A (en) Multilayer controlled release tablets containing both naproxen and naproxen sodium salt
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
USD484322S1 (en) Baby chair
PL346764A1 (en) New oral formulation for 5-ht4
JP2001513506A5 (de)
DE60231997D1 (de) Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
NO954952L (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
JPS6413019A (en) Aldose reductase inhibitor
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
AU2003202550A1 (en) Pharmaceutical formulations with modified release
WO2001028570A3 (en) Zinc lactate lozenges and uses thereof
JP2003502270A5 (de)
PE20001038A1 (es) Uso de cetiricina para la prevencion del inicio del asma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties